SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q3 FY20 results · Oct–Dec 2019
SMS Pharmaceuticals reported revenue from operations of ₹80.45 crore and net profit of ₹7.50 crore for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 80.45 | — | — | 117.90 | −31.8% |
| Other income | 0.79 | — | — | 0.58 | +36.4% |
| Total income | 81.24 | — | — | 118.48 | −31.4% |
| Profit before tax | 12.50 | — | — | 14.42 | −13.3% |
| Net profit for the period | 7.50 | — | — | 9.55 | −21.4% |
| EPS, basic (₹) | 0.90 | — | — | 1.17 | −23.1% |
| Net margin (%) | 9.3 | — | 8.1 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 80.45 | 101.25 | −20.5% | 117.90 | −31.8% |
| Other income | 0.79 | 0.59 | +33.5% | 0.58 | +36.4% |
| Total income | 81.24 | 101.85 | −20.2% | 118.48 | −31.4% |
| Profit before tax | 12.50 | 18.64 | −32.9% | 14.42 | −13.3% |
| Net profit for the period | 7.50 | 12.19 | −38.5% | 9.55 | −21.4% |
| EPS, basic (₹) | 0.89 | 1.44 | −38.2% | 1.13 | −21.2% |
| Net margin (%) | 9.3 | 12.0 | 8.1 |
Consolidated
- Filed with BSE
- 13 Feb 2020, 15:32 IST
- Board meeting
- 12 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Feb 2020, 15:32 IST
- Board meeting
- 12 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE